Celltrion and Abpro will present preclinical data on their multispecific antibody cancer therapy CT-P72/ABP-102 at SITC 2025, targeting IND submission this year and first-in-human trials in 2025, after demonstrating strong efficacy and safety in preclinical studies.
#YonhapInfomax #Celltrion #Abpro #CTP72ABP102 #SITC2025 #ImmunoOncology #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89243